Chapter 15: Antiepileptic Drugs – Seizure Control & Mechanisms

Antiepileptic Drugs – Seizure Control & Mechanisms pharmacology chapter comprehensively examines the clinical management of epilepsy, a chronic neurological disorder characterized by recurrent episodes of seizures resulting from excessive electrical activity in the cerebral cortex. The discussion distinguishes between a seizure (abnormal neuronal stimulation), a convulsion (spasmodic contraction of voluntary muscles), and epilepsy (the chronic condition), detailing the modern classifications, which include focal onset, generalized onset, and unknown onset seizures. The primary objective of Antiepileptic Drug (AED) therapy is to prevent or minimize seizure incidence while maintaining the patient’s quality of life, ideally achieved through single-drug therapy (monotherapy). AEDs exert their effects primarily by stabilizing neuronal membranes, increasing the activation threshold in the motor cortex, and limiting the spread of electrical discharges, often by manipulating ion movement (sodium, potassium, calcium, magnesium) or enhancing the inhibitory effects of GABA. Key traditional drug classes reviewed include hydantoins (phenytoin), barbiturates (phenobarbital), and iminostilbenes (carbamazepine), alongside newer miscellaneous agents like gabapentin, lamotrigine, and valproic acid. Crucial considerations in therapy include the need for Therapeutic Drug Monitoring (TDM) due to the narrow therapeutic index of many AEDs, the risk of serious adverse effects such as potentially fatal skin rashes (Stevens-Johnson syndrome) and gingival hyperplasia (phenytoin), and significant drug interactions (e.g., enzyme induction/inhibition). Furthermore, the chapter addresses status epilepticus, defined as a medical emergency involving prolonged or recurrent seizure activity, which requires immediate and aggressive intervention, often starting with IV drugs like lorazepam. The accompanying nursing process emphasizes thorough baseline neurological assessment, monitoring laboratory parameters (CBC, liver/kidney function), ensuring strict adherence to dosing schedules (never abruptly stopping medication), and extensive patient education regarding safety measures, including avoiding abrupt withdrawal to prevent rebound seizures and adherence to driving restrictions.